187 related articles for article (PubMed ID: 34893458)
1. Adjuvant Radiotherapy After Radical Cystectomy for Patients with High-risk Muscle-invasive Bladder Cancer: Results of a Multicentric Phase II Trial.
Fonteyne V; Dirix P; Van Praet C; Berghen C; Albersen M; Junius S; Liefhooghe N; Noé L; De Meerleer G; Ost P; Villeirs G; Verbeke S; De Maeseneer D; Rammant E; Verghote F; Elhaseen E; De Man K; Decaestecker K
Eur Urol Focus; 2022 Sep; 8(5):1238-1245. PubMed ID: 34893458
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: a phase II trial.
Fonteyne V; Dirix P; Junius S; Rammant E; Ost P; De Meerleer G; Swimberghe M; Decaestecker K
BMC Cancer; 2017 May; 17(1):308. PubMed ID: 28464906
[TBL] [Abstract][Full Text] [Related]
3. Study Protocol of the Bladder Adjuvant RadioTherapy (BART) Trial: A Randomised Phase III Trial of Adjuvant Radiotherapy Following Cystectomy in Bladder Cancer.
Murthy V; Maitre P; Singh M; Pal M; Arora A; Pujari L; Kapoor A; Pandey H; Sharma R; Gudipudi D; Joshi A; Prabhash K; Noronha V; Menon S; Mehta P; Bakshi G; Prakash G
Clin Oncol (R Coll Radiol); 2023 Sep; 35(9):e506-e515. PubMed ID: 37208232
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: A retrospective multicenter study.
Orré M; Latorzeff I; Fléchon A; Roubaud G; Brouste V; Gaston R; Piéchaud T; Richaud P; Chapet O; Sargos P
PLoS One; 2017; 12(4):e0174978. PubMed ID: 28384195
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
Vetterlein MW; Seisen T; May M; Nuhn P; Gierth M; Mayr R; Fritsche HM; Burger M; Novotny V; Froehner M; Wirth MP; Protzel C; Hakenberg OW; Roghmann F; Palisaar RJ; Noldus J; Pycha A; Bastian PJ; Trinh QD; Xylinas E; Shariat SF; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A;
Eur Urol Focus; 2018 Mar; 4(2):252-259. PubMed ID: 28753775
[TBL] [Abstract][Full Text] [Related]
6. National Practice Patterns and Overall Survival After Adjuvant Radiotherapy Following Radical Cystectomy for Urothelial Bladder Cancer in the USA, 2004-2013.
Bateni ZH; Pearce SM; Zainfeld D; Ballas L; Djaladat H; Schuckman AK; Daneshmand S
Eur Urol Oncol; 2020 Jun; 3(3):343-350. PubMed ID: 31317867
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy.
Sargos P; Baumann BC; Eapen L; Christodouleas J; Bahl A; Murthy V; Efstathiou J; Fonteyne V; Ballas L; Zaghloul M; Roubaud G; Orré M; Larré S
Cancer Treat Rev; 2018 Nov; 70():88-97. PubMed ID: 30125800
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Radiotherapy Use by US Radiation Oncologists After Radical Cystectomy for Muscle-invasive Bladder Cancer.
Solanki AA; Martin B; Korpics M; Small C; Harkenrider MM; Mitin T
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):429-435. PubMed ID: 28242163
[TBL] [Abstract][Full Text] [Related]
9. Lymphovascular invasion and the presence of more than three tumors are associated with poor outcomes of muscle-invasive bladder cancer after bladder-conserving therapies.
Zhang M; Tao R; Zhang C; Shen Z
Urology; 2010 Oct; 76(4):902-7. PubMed ID: 20709377
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.
Zaghloul MS; Christodouleas JP; Smith A; Abdallah A; William H; Khaled HM; Hwang WT; Baumann BC
JAMA Surg; 2018 Jan; 153(1):e174591. PubMed ID: 29188298
[TBL] [Abstract][Full Text] [Related]
11. Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer.
Navarro-Domenech I; Arulanantham S; Liu ZA; Tjong M; Kong V; Malkov V; Tadic T; Fleshner N; Kulkarni G; Zlotta AR; Catton C; Berlin A; Sridhar S; Jiang DM; Chung P; Raman S
Radiat Oncol; 2023 Sep; 18(1):154. PubMed ID: 37730609
[TBL] [Abstract][Full Text] [Related]
12. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
[TBL] [Abstract][Full Text] [Related]
13. Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium.
Mir MC; Marchioni M; Zargar H; Zargar-Shoshtari K; Fairey AS; Mertens LS; Dinney CP; Krabbe LM; Cookson MS; Jacobsen NE; Griffin J; Montgomery JS; Vasdev N; Yu EY; Xylinas E; McGrath JS; Kassouf W; Dall'Era MA; Sridhar SS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Daneshmand D; Black PC
Eur Urol Focus; 2021 Nov; 7(6):1347-1354. PubMed ID: 32771446
[TBL] [Abstract][Full Text] [Related]
14. The role of combined method in organ-sparing treatment of muscle-invasive bladder cancer recurrences.
Startsev VY
Arch Ital Urol Androl; 2002 Jun; 74(2):54-6. PubMed ID: 12161935
[TBL] [Abstract][Full Text] [Related]
15. Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.
Hall E; Hussain SA; Porta N; Lewis R; Crundwell M; Jenkins P; Rawlings C; Tremlett J; Sreenivasan T; Wallace J; Syndikus I; Sheehan D; Lydon A; Huddart R; James N;
Eur Urol; 2022 Sep; 82(3):273-279. PubMed ID: 35577644
[TBL] [Abstract][Full Text] [Related]
16. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
[TBL] [Abstract][Full Text] [Related]
17. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
[TBL] [Abstract][Full Text] [Related]
18. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
[TBL] [Abstract][Full Text] [Related]
19. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
Szabados B; Kockx M; Assaf ZJ; van Dam PJ; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; Tyson C; Stanoeva D; Daelemans S; Rombouts M; Mariathasan S; Tea JS; Mousa K; Sharma S; Aleshin A; Banchereau R; Castellano D; Powles T
Eur Urol; 2022 Aug; 82(2):212-222. PubMed ID: 35577646
[TBL] [Abstract][Full Text] [Related]
20. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients.
Hautmann RE; de Petriconi RC; Pfeiffer C; Volkmer BG
Eur Urol; 2012 May; 61(5):1039-47. PubMed ID: 22381169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
